CSM Advisors LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 1.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,238 shares of the medical research company’s stock after buying an additional 75 shares during the quarter. CSM Advisors LLC’s holdings in Amgen were worth $1,404,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the company. L & S Advisors Inc grew its holdings in shares of Amgen by 882.6% during the fourth quarter. L & S Advisors Inc now owns 11,870 shares of the medical research company’s stock worth $2,670,000 after buying an additional 10,662 shares in the last quarter. Benedict Financial Advisors Inc. grew its holdings in shares of Amgen by 3.1% during the fourth quarter. Benedict Financial Advisors Inc. now owns 30,455 shares of the medical research company’s stock worth $6,852,000 after buying an additional 926 shares in the last quarter. Biechele Royce Advisors grew its holdings in shares of Amgen by 9.6% during the fourth quarter. Biechele Royce Advisors now owns 54,154 shares of the medical research company’s stock worth $12,183,000 after buying an additional 4,736 shares in the last quarter. Washington Trust Bank grew its holdings in shares of Amgen by 11.5% during the fourth quarter. Washington Trust Bank now owns 3,724 shares of the medical research company’s stock worth $837,000 after buying an additional 384 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its position in shares of Amgen by 8.0% during the 4th quarter. Lazard Asset Management LLC now owns 95,070 shares of the medical research company’s stock valued at $21,386,000 after acquiring an additional 7,072 shares during the last quarter. 79.01% of the stock is owned by institutional investors and hedge funds.
AMGN has been the topic of several recent research reports. Wells Fargo & Company boosted their price target on shares of Amgen from $210.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 9th. Jefferies Financial Group boosted their price target on shares of Amgen from $266.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, February 9th. Oppenheimer cut shares of Amgen to an “outperform” rating and set a $285.00 price target on the stock. in a research report on Tuesday. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 5th. Finally, Bank of America cut shares of Amgen from a “buy” rating to a “neutral” rating and lowered their price target for the company from $285.00 to $255.00 in a research report on Wednesday, January 5th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $240.00.
Amgen (NASDAQ:AMGN – Get Rating) last issued its quarterly earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.10 by $0.15. Amgen had a return on equity of 165.95% and a net margin of 21.75%. During the same quarter in the prior year, the firm earned $3.70 earnings per share. Analysts anticipate that Amgen Inc. will post 17.49 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Shareholders of record on Tuesday, May 17th will be issued a $1.94 dividend. This represents a $7.76 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date of this dividend is Monday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 76.38%.
About Amgen (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Peak Growth Is Over For Etsy
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Uber Fails To Impress
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.